Voss Capital LP Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Voss Capital LP bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 275,000 shares of the company's stock, valued at approximately $1,510,000. Voss Capital LP owned about 0.18% of Xeris Biopharma as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. NewEdge Advisors LLC purchased a new position in Xeris Biopharma during the fourth quarter worth approximately $34,000. Apella Capital LLC purchased a new position in Xeris Biopharma during the first quarter worth approximately $55,000. Xponance Inc. purchased a new position in Xeris Biopharma during the first quarter worth approximately $57,000. FNY Investment Advisers LLC purchased a new position in Xeris Biopharma during the first quarter worth approximately $63,000. Finally, Raymond James Financial Inc. purchased a new position in Xeris Biopharma during the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Stock Up 2.1%

Shares of NASDAQ XERS traded up $0.16 during midday trading on Friday, hitting $7.75. The stock had a trading volume of 1,699,218 shares, compared to its average volume of 3,363,119. The company has a market capitalization of $1.25 billion, a PE ratio of -36.90 and a beta of 0.65. The stock has a 50 day simple moving average of $5.53 and a 200-day simple moving average of $4.86. Xeris Biopharma Holdings, Inc. has a 1 year low of $2.48 and a 1 year high of $7.79.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on XERS. Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. HC Wainwright initiated coverage on Xeris Biopharma in a research report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target on the stock. Leerink Partners raised their target price on Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Tuesday, August 19th. Finally, Oppenheimer raised their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $7.08.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, Director Dawn Halkuff sold 42,500 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the sale, the director directly owned 115,000 shares in the company, valued at $837,200. This represents a 26.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin Mcculloch bought 25,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares in the company, valued at $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.56% of the stock is owned by company insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.